{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T17:58:33Z","timestamp":1791655113058,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2011,9,1]],"date-time":"2011-09-01T00:00:00Z","timestamp":1314835200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2011,9]]},"DOI":"10.1016\/j.exer.2011.03.001","type":"journal-article","created":{"date-parts":[[2011,3,16]],"date-time":"2011-03-16T14:30:18Z","timestamp":1300285818000},"page":"250-255","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":90,"title":["Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating Prostaglandin F2\u03b1 agonist, in preclinical models"],"prefix":"10.1016","volume":"93","author":[{"given":"Achim H.P.","family":"Krauss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Impagnatiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carol B.","family":"Toris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Gale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ganesh","family":"Prasanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Borghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio","family":"Chiroli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley K.M.","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha T.","family":"Carreiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ennio","family":"Ongini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2011.03.001_bib1","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1089\/jop.2009.0120","article-title":"A\u00a0novel nitric oxide releasing prostaglandin analog, NCX 125, reduces intraocular pressure in rabbit, dog, and primate models of glaucoma","volume":"26","author":"Borghi","year":"2010","journal-title":"J.\u00a0Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.exer.2011.03.001_bib4","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/S0161-6420(96)30749-5","article-title":"Comparison of latanoprost and timolol in patients with ocular hypertension and glaucoma. A 6-month, masked, multicenter trial in the United States","volume":"103","author":"Camras","year":"1996","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2011.03.001_bib2","doi-asserted-by":"crossref","first-page":"205","DOI":"10.3109\/02713688109001850","article-title":"Reduction of intraocular pressure in normal and glaucomatous primate (Aotus trivirgatus) eyes by topically applied prostaglandin F2 alpha","volume":"1","author":"Camras","year":"1981","journal-title":"Curr. Eye Res."},{"key":"10.1016\/j.exer.2011.03.001_bib3","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1001\/archopht.1992.01080240073034","article-title":"Intraocular pressure reduction with PhXA34, a new prostaglandin analogue, in patients with ocular hypertension","volume":"110","author":"Camras","year":"1992","journal-title":"Arch. Ophthalmol."},{"key":"10.1016\/j.exer.2011.03.001_bib5","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/112067210201200109","article-title":"Decreased nitric oxide production in primary open-angle glaucoma","volume":"12","author":"Doganay","year":"2002","journal-title":"Eur. J. Ophthalmol."},{"key":"10.1016\/j.exer.2011.03.001_bib6","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/0014-4835(89)90049-3","article-title":"Prostaglandin F2 alpha increases uveoscleral outflow in the cynomolgus monkey","volume":"49","author":"Gabelt","year":"1989","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2011.03.001_bib7","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/bjo.2003.028357","article-title":"Nitric oxide proxies and ocular perfusion pressure in primary open angle glaucoma","volume":"88","author":"Galassi","year":"2004","journal-title":"Br. J. Ophthalmol."},{"key":"10.1016\/j.exer.2011.03.001_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.bjp.0702495","article-title":"Effects of the soluble guanylyl cyclase activator, YC-1, on vascular tone, cyclic GMP levels and phosphodiesterase activity","volume":"127","author":"Galle","year":"1999","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.exer.2011.03.001_bib9","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1046\/j.1463-5216.2001.00201.x","article-title":"Effect of different dose schedules of latanoprost on intraocular pressure and pupil size in the glaucomatous beagle","volume":"4","author":"Gelatt","year":"2001","journal-title":"Vet. Ophthalmol."},{"key":"10.1016\/j.exer.2011.03.001_bib10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1089\/108076802317233171","article-title":"Comparison of nitric oxide donors in lowering intraocular pressure in rabbits: role of cyclic GMP","volume":"18","author":"Kotikoski","year":"2002","journal-title":"J.\u00a0Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.exer.2011.03.001_bib11","first-page":"2214","article-title":"Prostaglandins alter extracellular matrix adjacent to human ciliary muscle cells in vitro","volume":"38","author":"Lindsey","year":"1997","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2011.03.001_bib12","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/0014-4835(88)90043-7","article-title":"Morphological study of the anterior segment of cynomolgus monkey eyes following treatment with prostaglandin F2\u03b1","volume":"47","author":"L\u00fctjen-Drecoll","year":"1988","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2011.03.001_bib13","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0022-3565(25)11469-9","article-title":"Nitrovasodilators as a new class of ocular hypotensive agents","volume":"260","author":"Nathanson","year":"1992","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.exer.2011.03.001_bib14","first-page":"1774","article-title":"Alterations of ocular nitric oxide synthase in human glaucoma","volume":"36","author":"Nathanson","year":"1995","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2011.03.001_bib15","first-page":"1765","article-title":"Identification of an extensive system of nitric oxide-producing cells in the ciliary muscle and outflow pathway of the human eye","volume":"36","author":"Nathanson","year":"1995","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2011.03.001_bib16","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/0014-4835(89)90011-0","article-title":"Increased uveoscleral outflow as a possible mechanism of ocular hypotension caused by prostaglandin F2\u03b1-1-isopropylester in the cynomolgus monkey","volume":"48","author":"Nilsson","year":"1989","journal-title":"Exp. Eye. Res."},{"key":"10.1016\/j.exer.2011.03.001_bib17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1248\/bpb.28.65","article-title":"Potent reduction of intraocular pressure by nipradilol plus latanoprost in ocular hypertensive rabbits","volume":"28","author":"Orihashi","year":"2005","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.exer.2011.03.001_bib18","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0039-6257(97)80007-0","article-title":"Structure-activity relationships and receptor profiles of some ocular hypotensive prostanoids","volume":"41","author":"Resul","year":"1997","journal-title":"Surv. Ophthalmol."},{"key":"10.1016\/j.exer.2011.03.001_bib19","doi-asserted-by":"crossref","first-page":"4419","DOI":"10.1167\/iovs.02-1281","article-title":"Morphological changes in the anterior eye segment after long-term treatment with different receptor selective prostaglandin agonists and a prostamide","volume":"44","author":"Richter","year":"2003","journal-title":"Invest. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2011.03.001_bib20","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/ICU.0b013e3282f493b3","article-title":"Risk factors for primary open angle glaucoma progression: what we know and what we need to know","volume":"19","author":"Rivera","year":"2008","journal-title":"Curr. Opin. Ophthalmol."},{"key":"10.1016\/j.exer.2011.03.001_bib21","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1006\/exer.1994.1199","article-title":"Nitrovasodilator effects on intraocular pressure and outflow facility in monkeys","volume":"58","author":"Schuman","year":"1994","journal-title":"Exp. Eye Res."},{"key":"10.1016\/j.exer.2011.03.001_bib23","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/108076803322660422","article-title":"Ocular hypotensive FP prostaglandin (PG) analogs: PG receptor subtype binding affinities and selectivities, and agonist potencies at FP and other PG receptors in cultured cells","volume":"19","author":"Sharif","year":"2003","journal-title":"J.\u00a0Ocul. Pharmacol. Ther."},{"key":"10.1016\/j.exer.2011.03.001_bib24","first-page":"745","article-title":"The pharmacokinetics of a new antiglaucoma drug, latanoprost, in the rabbit","volume":"26","author":"Sj\u00f6quist","year":"1998","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.exer.2011.03.001_bib22","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/j.ophtha.2007.10.004","article-title":"Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines","volume":"115","author":"Stewart","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2011.03.001_bib25","first-page":"513","article-title":"Preclinical pharmacology of latanoprost, a phenyl-substituted PGF2 alpha analogue","volume":"23","author":"Stjernschantz","year":"1995","journal-title":"Adv. Prostaglandin Thromboxane Leukot. Res."},{"key":"10.1016\/j.exer.2011.03.001_bib26","first-page":"1838","article-title":"Prostaglandin F2 alpha effects on intraocular pressure negatively correlate with FP-receptor stimulation","volume":"30","author":"Woodward","year":"1989","journal-title":"Invest. Ophthalmol. Vis. Sci."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483511000790?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483511000790?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T04:54:32Z","timestamp":1757998472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483511000790"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,9]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,9]]}},"alternative-id":["S0014483511000790"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2011.03.001","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2011,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocular hypotensive activity of BOL-303259-X, a nitric oxide donating Prostaglandin F2\u03b1 agonist, in preclinical models","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2011.03.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2011 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}